
Zhejiang Wolwo Bio-Pharma is a biotechnology company focused on diagnosing and treating allergic diseases.
wolwobiotech.comCrawled Nov 8, 2026
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. announces a proposed cash dividend of **CNY 2.50 per share** (tax included) for its shareholders for the third quarter of 2026. The dividend applies to holders of 10 shares or more. The company operates in the biopharmaceutical sector, though no additional financial or operational details are provided in the announcement.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. reports **CNY 910 million in sales and revenue** for the nine months ending September 30, 2026. This marks a year-over-year increase from CNY 853.36 million in the same period of the prior year. The company’s financial results reflect growth in its pharmaceutical operations over the latest quarterly period.
Zhejiang Wolwo Bio-Pharmaceutical Co experiences a 2.23% decline in stock value. The company operates in the biopharmaceutical sector, though specific details about the drop are not provided in the report.
Wolwo Bio’s subsidiary secures Chinese regulatory approval to begin clinical trials for a sepsis treatment using umbilical cord mesenchymal stem cells. The therapy targets sepsis, a life-threatening condition with limited treatment options. Wolwo Bio aims to pursue global regulatory approvals, positioning itself as a potential first mover in this therapeutic area.
Wolwo Bio’s co-founders Hu Gengxi and Chen Yanni dissolved their marriage and divided their 47.2% stake in the A-share-listed desensitization treatment company, valued at **5.423 billion yuan ($809.9M)**. Hu Gengxi also resigned as chairman following the split. The transaction reflects China’s largest controlling-shareholder divorce equity divisions.